Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiviral prophylaxis to prevent CMV reactivation in critically ill immunocompetent adults
2010-024646-30Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Jan 2011
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of valganciclovir and valaciclovir in cytomegalovirus disease (CMV) (3 arms), sponsored by University Hospitals Birmingham. Primary endpoint: Cytomegalovirus reactivation in blood. Started Jan 2011; status: completed.
02
Drugs
valganciclovirvalaciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2010-024646-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024646-30.